France based IBA Molecular to acquire Nuclear Imaging business of Mallinckrodt for $690 million. The transaction is subject to customary closing conditions.
With this deal more than 800 workforce’s as well as two manufacturing facilities will be in IBA Molecular’s hands from Mallinckrodt.
About IBA MolecularIBA Molecular is France based company that produces radioactive tracers used in molecular imaging and therapy to diagnose and monitor common diseases. The company offers PET radiopharmaceuticals; SPECT and therapy products, such as radiopharmaceuticals, cold kits, and accessories; and radiochemicals.
The company was founded in 2012 and is based in Gif-sur-Yvette, France.
Mallinckrodt Pharmaceuticals, based in Staines-upon-Thames, England, with its U.S. headquarters in St. Louis, Missouri, produces specialty pharmaceutical products, including generic drugs and imaging agents.
Mallinckrodt manufactures and distributes products used in diagnostic procedures and in the treatment of pain and related conditions. This includes the development, manufacture and distribution of specialty pharmaceuticals, active pharmaceutical ingredients, contrast products and radiopharmaceuticals.